Home › Lung Diseases › Tennessee
Lung Diseases clinical trials in Tennessee
15 studies for Lung Diseases are looking for participants at sites in Tennessee.
Cities in Tennessee
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
- West Tennessee Research Institute, Jackson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07013474Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- University of Tennessee Medical Center, Knoxville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07489066A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- WR-Clinsearch, LLC, Chattanooga
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT06679140American Lung Association (ALA) Lung Health Cohort
- Vanderbilt University Medical Center, Nashville
RecruitingObservational studyHealthy volunteers welcome
Ages 25 to 35 · All sexes · Updated Sep 23, 2026 · NCT04543461A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
- Premier Research Center, LLC, Hendersonville
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Sep 22, 2026 · NCT06977581Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Tennessee Oncology Chattanooga, Chattanooga
- University of Tennessee Medical Center, Knoxville
- Baptist Memorial Hospital-Memphis, Memphis
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 4, 2026 · NCT07059091Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
- Clinical Trials Center of Middle Tennesee LLC, Franklin
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Sep 3, 2026 · NCT07284602A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
- SCRI Oncology Partners, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT05967689Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- SCRI Oncology Partners, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT06765109Cooperative Assessment of Late Effects for SCD Curative Therapies
- Vanderbilt University Medical Center, Nashville
RecruitingObservational study
Ages 4 to 65 · All sexes · Updated Jul 27, 2026 · NCT05153967Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- University of Tennessee Medical Center, Knoxville
- Baptist Cancer Center, Memphis
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jun 26, 2026 · NCT04614103A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Baptist Memorial Hospital Baptist Cancer Center, Memphis
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Tristar Bone Marrow Transplant, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.